@fda.gov grants accelerated approval to the first EGFR/MET-targeted therapy for advanced head and neck cancer 🧬
Link in the comments 👇
#HeadAndNeckCancer #HNSCC #Amivantamab #BispecificAntibodies #CancerResearch #Oncology #TargetedTherapy
Link in the comments 👇
#HeadAndNeckCancer #HNSCC #Amivantamab #BispecificAntibodies #CancerResearch #Oncology #TargetedTherapy
November 9, 2026 at 6:35 PM
@fda.gov grants accelerated approval to the first EGFR/MET-targeted therapy for advanced head and neck cancer 🧬
Link in the comments 👇
#HeadAndNeckCancer #HNSCC #Amivantamab #BispecificAntibodies #CancerResearch #Oncology #TargetedTherapy
Link in the comments 👇
#HeadAndNeckCancer #HNSCC #Amivantamab #BispecificAntibodies #CancerResearch #Oncology #TargetedTherapy
Researchers at the University of Chicago engineered CAR T cells that release the cytokine TNF only when the tumor is irradiated, driving far greater tumor regression than either treatment alone. #CARTTherapy #TargetedTherapy #Immunotherapy
https://ow.ly/5sTR5105rRf
https://ow.ly/5sTR5105rRf
Novel CAR-T platform uses radiation-activated switch to destroy tumors more effectively - UChicago Medicine
UChicago researchers developed a new and effective CAR T-cell platform to treat therapy-resistant cancer using radiation activated by a molecular switch.
ow.ly
November 10, 2026 at 3:52 PM
Researchers at the University of Chicago engineered CAR T cells that release the cytokine TNF only when the tumor is irradiated, driving far greater tumor regression than either treatment alone. #CARTTherapy #TargetedTherapy #Immunotherapy
https://ow.ly/5sTR5105rRf
https://ow.ly/5sTR5105rRf
Encouraging news for lung cancer patients. ZEGFROVY, a once-daily targeted tablet, is now available in the US for certain patients with EGFR exon 20 mutations after chemotherapy. Trials showed a 46% tumour response rate.
www.cancernetwork.com/view/sunvoze...
#LungCancer #TargetedTherapy #TCSC
www.cancernetwork.com/view/sunvoze...
#LungCancer #TargetedTherapy #TCSC
Sunvozertinib Now Available in US for EGFR Exon 20+ NSCLC | CancerNetwork
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
www.cancernetwork.com
October 23, 2026 at 10:16 AM
Encouraging news for lung cancer patients. ZEGFROVY, a once-daily targeted tablet, is now available in the US for certain patients with EGFR exon 20 mutations after chemotherapy. Trials showed a 46% tumour response rate.
www.cancernetwork.com/view/sunvoze...
#LungCancer #TargetedTherapy #TCSC
www.cancernetwork.com/view/sunvoze...
#LungCancer #TargetedTherapy #TCSC
Last week, CSI Singapore hosted Dr. Anwesha Dey from Genentech. She spoke on the topic “Targeting the PI3K Pathway in Cancers”.
#PI3Kpathway #targetedtherapy #precisionmedicine #molecularoncology #cancerresearch #oncologyresearch #biomedicalresearch
#PI3Kpathway #targetedtherapy #precisionmedicine #molecularoncology #cancerresearch #oncologyresearch #biomedicalresearch
October 16, 2026 at 4:14 AM
Last week, CSI Singapore hosted Dr. Anwesha Dey from Genentech. She spoke on the topic “Targeting the PI3K Pathway in Cancers”.
#PI3Kpathway #targetedtherapy #precisionmedicine #molecularoncology #cancerresearch #oncologyresearch #biomedicalresearch
#PI3Kpathway #targetedtherapy #precisionmedicine #molecularoncology #cancerresearch #oncologyresearch #biomedicalresearch
Could combining anti-CD38 #antibodies improve MM treatment? This study shows #isatuximab & daratumumab bind non-competitively, with distinct apoptosis profiles. Pomalidomide enhances isatuximab-induced cell death!
👉 www.mdpi.com/1999-4923/17...
#MultipleMyeloma #CD38 #TargetedTherapy #Immunotherapy
👉 www.mdpi.com/1999-4923/17...
#MultipleMyeloma #CD38 #TargetedTherapy #Immunotherapy
October 12, 2026 at 10:48 AM
Could combining anti-CD38 #antibodies improve MM treatment? This study shows #isatuximab & daratumumab bind non-competitively, with distinct apoptosis profiles. Pomalidomide enhances isatuximab-induced cell death!
👉 www.mdpi.com/1999-4923/17...
#MultipleMyeloma #CD38 #TargetedTherapy #Immunotherapy
👉 www.mdpi.com/1999-4923/17...
#MultipleMyeloma #CD38 #TargetedTherapy #Immunotherapy
The anti-TFRC antibody PPMX-T003 suppresses #ColorectalCancer growth and metastatic colonization in preclinical models, highlighting iron-dependent tumor survival as a target for limiting metastatic progression.
#STTT #OpenAccess: doi.org/10.1038/s413...
#AntibodyTherapy #TargetedTherapy
#STTT #OpenAccess: doi.org/10.1038/s413...
#AntibodyTherapy #TargetedTherapy
September 30, 2026 at 5:35 AM
The anti-TFRC antibody PPMX-T003 suppresses #ColorectalCancer growth and metastatic colonization in preclinical models, highlighting iron-dependent tumor survival as a target for limiting metastatic progression.
#STTT #OpenAccess: doi.org/10.1038/s413...
#AntibodyTherapy #TargetedTherapy
#STTT #OpenAccess: doi.org/10.1038/s413...
#AntibodyTherapy #TargetedTherapy
Breaking: Spanish researchers at CNIC have identified a shared molecular mechanism in hypertrophic cardiomyopathy th…
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedheartdisease #Molecularmechanism #Targetedtherapy
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedhea…
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedheartdisease #Molecularmechanism #Targetedtherapy
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedhea…
Heart disease mechanism breakthrough: unified therapy approach
Breaking: Spanish researchers at CNIC have identified a shared molecular mechanism in hypertrophic cardiomyopathy th…
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedheartdisease #Molecularmechanism #Targetedtherapy
news.gmj.ge
September 29, 2026 at 9:26 AM
Breaking: Spanish researchers at CNIC have identified a shared molecular mechanism in hypertrophic cardiomyopathy th…
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedheartdisease #Molecularmechanism #Targetedtherapy
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedhea…
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedheartdisease #Molecularmechanism #Targetedtherapy
#Cardiovascularresearch #Hypertrophiccardiomyopathy #Inheritedhea…
🔬 A new investigational targeted therapy combined with standard chemotherapy has shown promise in advanced pancreatic cancer, according to early data …
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcancer #Targetedtherapy
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcance…
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcancer #Targetedtherapy
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcance…
Pancreatic Cancer Therapy Shows Early Promise
🔬 A new investigational targeted therapy combined with standard chemotherapy has shown promise in advanced pancreatic cancer, according to early data …
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcancer #Targetedtherapy
news.gmj.ge
September 28, 2026 at 3:26 PM
🔬 A new investigational targeted therapy combined with standard chemotherapy has shown promise in advanced pancreatic cancer, according to early data …
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcancer #Targetedtherapy
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcance…
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcancer #Targetedtherapy
#Biomarkerdriventreatment #ESMO2026 #Oncology #Pancreaticcance…
Oncology Precision Medicine Market Size, Trends, and Growth Outlook 2026-2033
www.coherentcmi.com/industry-rep...
#CancerTreatment #TargetedTherapy #CancerCare #LiquidBiopsy #MedicalResearch #HealthcareTechnology #MedTech #MarketResearch #GlobalMarket
www.coherentcmi.com/industry-rep...
#CancerTreatment #TargetedTherapy #CancerCare #LiquidBiopsy #MedicalResearch #HealthcareTechnology #MedTech #MarketResearch #GlobalMarket
September 22, 2026 at 6:30 AM
Oncology Precision Medicine Market Size, Trends, and Growth Outlook 2026-2033
www.coherentcmi.com/industry-rep...
#CancerTreatment #TargetedTherapy #CancerCare #LiquidBiopsy #MedicalResearch #HealthcareTechnology #MedTech #MarketResearch #GlobalMarket
www.coherentcmi.com/industry-rep...
#CancerTreatment #TargetedTherapy #CancerCare #LiquidBiopsy #MedicalResearch #HealthcareTechnology #MedTech #MarketResearch #GlobalMarket
Encouraging results in HER2-mutant lung cancer. Enhertu achieved median progression-free survival of 14.3 months versus 8.3 months with chemotherapy plus immunotherapy in DESTINY-Lung04.
www.curetoday.com/view/enhertu...
#LungCancer #CancerResearch #TargetedTherapy #TCSC
www.curetoday.com/view/enhertu...
#LungCancer #CancerResearch #TargetedTherapy #TCSC
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing | CURE
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
www.curetoday.com
September 22, 2026 at 9:07 AM
Encouraging results in HER2-mutant lung cancer. Enhertu achieved median progression-free survival of 14.3 months versus 8.3 months with chemotherapy plus immunotherapy in DESTINY-Lung04.
www.curetoday.com/view/enhertu...
#LungCancer #CancerResearch #TargetedTherapy #TCSC
www.curetoday.com/view/enhertu...
#LungCancer #CancerResearch #TargetedTherapy #TCSC
Nafisa Ali reveals she has been put on Targeted Therapy as her cancer has progressed #NafisaAli #TargetedTherapy #socialnewsxyz
Nafisa Ali reveals she has been put on Targeted Therapy as her cancer has progressed
Mumbai, Sep 13 (SocialNews.XYZ) Veteran actress Nafisa Ali shared her health update through her latest post on Instagram. She revealed that she has been put on Targeted Therapy by her medical team as her cancer has progressed. On Sunday, Nafisa took to her official handle and published a picture of herself from the hospital. Expressing gratitude for all the support she has been getting during this challenging journey, the ‘Life in a... Metro’ actress wrote, "My treatment protocol has changed and now I have been put on Targeted Therapy… fighting the good fight .
www.socialnews.xyz
September 13, 2026 at 5:21 AM
Nafisa Ali reveals she has been put on Targeted Therapy as her cancer has progressed #NafisaAli #TargetedTherapy #socialnewsxyz
Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #cancerresistance #targetedtherapy #oncology #openaccess
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #cancerresistance #targetedtherapy #oncology #openaccess
September 11, 2026 at 9:22 PM
Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #cancerresistance #targetedtherapy #oncology #openaccess
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #cancerresistance #targetedtherapy #oncology #openaccess
#Targetome
CLDN18.2 emerges as a promising PDAC therapeutic target, with monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates showing clinical progress.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0033
#CLDN18.2 #TargetedTherapy
CLDN18.2 emerges as a promising PDAC therapeutic target, with monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates showing clinical progress.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0033
#CLDN18.2 #TargetedTherapy
September 7, 2026 at 12:39 AM
#Targetome
CLDN18.2 emerges as a promising PDAC therapeutic target, with monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates showing clinical progress.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0033
#CLDN18.2 #TargetedTherapy
CLDN18.2 emerges as a promising PDAC therapeutic target, with monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates showing clinical progress.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0033
#CLDN18.2 #TargetedTherapy
Can smarter #DrugDelivery improve #SpinalCordInjury repair?
This review highlights how #nanoparticles enhance #targetedtherapy and controlled release, offering new possibilities for more effective SCI treatment.
#OpenAccess in #NanotechnologyReviews: doi.org/10.1515/ntre...
#Nanomedicine
This review highlights how #nanoparticles enhance #targetedtherapy and controlled release, offering new possibilities for more effective SCI treatment.
#OpenAccess in #NanotechnologyReviews: doi.org/10.1515/ntre...
#Nanomedicine
September 6, 2026 at 6:30 AM
Can smarter #DrugDelivery improve #SpinalCordInjury repair?
This review highlights how #nanoparticles enhance #targetedtherapy and controlled release, offering new possibilities for more effective SCI treatment.
#OpenAccess in #NanotechnologyReviews: doi.org/10.1515/ntre...
#Nanomedicine
This review highlights how #nanoparticles enhance #targetedtherapy and controlled release, offering new possibilities for more effective SCI treatment.
#OpenAccess in #NanotechnologyReviews: doi.org/10.1515/ntre...
#Nanomedicine
Breakthrough in pediatric AML: Targeted therapies (FLT3/BCL-2/CDK6 inhibitors) significantly improve induction outcomes for high-risk NUP98-R AML!
doi.org/10.1007/s125...
#Leukemia #PediatricOncology #TargetedTherapy
doi.org/10.1007/s125...
#Leukemia #PediatricOncology #TargetedTherapy
August 27, 2026 at 8:17 AM
Breakthrough in pediatric AML: Targeted therapies (FLT3/BCL-2/CDK6 inhibitors) significantly improve induction outcomes for high-risk NUP98-R AML!
doi.org/10.1007/s125...
#Leukemia #PediatricOncology #TargetedTherapy
doi.org/10.1007/s125...
#Leukemia #PediatricOncology #TargetedTherapy
🧬🩺 Amivantamab is showing durable activity in a difficult-to-treat population with advanced head and neck cancer.
Read more ➡️ www.onclive.com/view/amivant...
#HeadAndNeckCancer #HNSCC #Amivantamab #TargetedTherapy #EGFR #MET #PrecisionOncology #Oncology
Read more ➡️ www.onclive.com/view/amivant...
#HeadAndNeckCancer #HNSCC #Amivantamab #TargetedTherapy #EGFR #MET #PrecisionOncology #Oncology
Amivantamab Monotherapy Yields Durable Responses in Pretreated R/M HNSCC | OncLive
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
www.onclive.com
August 25, 2026 at 5:38 PM
🧬🩺 Amivantamab is showing durable activity in a difficult-to-treat population with advanced head and neck cancer.
Read more ➡️ www.onclive.com/view/amivant...
#HeadAndNeckCancer #HNSCC #Amivantamab #TargetedTherapy #EGFR #MET #PrecisionOncology #Oncology
Read more ➡️ www.onclive.com/view/amivant...
#HeadAndNeckCancer #HNSCC #Amivantamab #TargetedTherapy #EGFR #MET #PrecisionOncology #Oncology
🚨🫁 Sevabertinib has been approved in Japan for the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC). 🧬📊
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Sevabertinib Approved in Japan for HER2-Mutant Non–Small Cell Lung Cancer | OncLive
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
www.onclive.com
August 24, 2026 at 6:08 PM
🚨🫁 Sevabertinib has been approved in Japan for the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC). 🧬📊
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Darlifarnib plus cabozantinib demonstrated encouraging safety and efficacy signals in patients with advanced renal cell carcinoma (RCC). 📊✨
Read more ➡️ www.onclive.com/view/darlifa...
#KidneyCancer #RCC #GUonc #Cabozantinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #Oncology #kcsm
Read more ➡️ www.onclive.com/view/darlifa...
#KidneyCancer #RCC #GUonc #Cabozantinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #Oncology #kcsm
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC | OncLive
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
www.onclive.com
August 23, 2026 at 6:19 PM
Darlifarnib plus cabozantinib demonstrated encouraging safety and efficacy signals in patients with advanced renal cell carcinoma (RCC). 📊✨
Read more ➡️ www.onclive.com/view/darlifa...
#KidneyCancer #RCC #GUonc #Cabozantinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #Oncology #kcsm
Read more ➡️ www.onclive.com/view/darlifa...
#KidneyCancer #RCC #GUonc #Cabozantinib #TargetedTherapy #PrecisionOncology #ClinicalTrials #Oncology #kcsm
Venclexta 100 mg tablets
www.drugsgeneral.com/venclexta-10...
#Venclexta #LeukemiaTreatment #CancerDrugs #CLL #AML #BCL2 #CancerFighter #CancerWarrior #PatientCommunity #LivingWithCancer #CancerSupport #TreatmentJourney#Hematology #Oncology #Pharmacy #Medication #TargetedTherapy
www.drugsgeneral.com/venclexta-10...
#Venclexta #LeukemiaTreatment #CancerDrugs #CLL #AML #BCL2 #CancerFighter #CancerWarrior #PatientCommunity #LivingWithCancer #CancerSupport #TreatmentJourney#Hematology #Oncology #Pharmacy #Medication #TargetedTherapy
Venclexta 100 mg Tablet Buy Online - India, USA, UK, UAE
Order Venclexta 100 mg Tablet (Venetoclax) online. Targeted therapy for CLL, SLL, and AML. Trusted source with global delivery at affordable prices.
www.drugsgeneral.com
September 16, 2025 at 5:00 AM
🌟💡Today’s clinical questions!
Swipe to see the answers and explanations!
#CMML #AML #Hematology #ClinicalHematology #HemeOnc #MedEd #MedicalEducation #ClinicalTrials #FDA #MyeloidNeoplasms #Leukemia #MyelodysplasticSyndrome #RASPathway #NRAS #MEKInhibitors #TargetedTherapy #HemeHub
Swipe to see the answers and explanations!
#CMML #AML #Hematology #ClinicalHematology #HemeOnc #MedEd #MedicalEducation #ClinicalTrials #FDA #MyeloidNeoplasms #Leukemia #MyelodysplasticSyndrome #RASPathway #NRAS #MEKInhibitors #TargetedTherapy #HemeHub
April 27, 2026 at 7:55 PM
🌟💡Today’s clinical questions!
Swipe to see the answers and explanations!
#CMML #AML #Hematology #ClinicalHematology #HemeOnc #MedEd #MedicalEducation #ClinicalTrials #FDA #MyeloidNeoplasms #Leukemia #MyelodysplasticSyndrome #RASPathway #NRAS #MEKInhibitors #TargetedTherapy #HemeHub
Swipe to see the answers and explanations!
#CMML #AML #Hematology #ClinicalHematology #HemeOnc #MedEd #MedicalEducation #ClinicalTrials #FDA #MyeloidNeoplasms #Leukemia #MyelodysplasticSyndrome #RASPathway #NRAS #MEKInhibitors #TargetedTherapy #HemeHub
🩸 Further insights on treatment options for CMML
#CMML #MyeloidMalignancies #Hematology #LeukemiaResearch #RASMutations #KRASInhibitors #TargetedTherapy #PanRAS #Immunotherapy #TIM3 #LILRB4 #MDSMPN #ClonalEvolution #MedicalEducation #HemeOnc #HEMEHUB
#CMML #MyeloidMalignancies #Hematology #LeukemiaResearch #RASMutations #KRASInhibitors #TargetedTherapy #PanRAS #Immunotherapy #TIM3 #LILRB4 #MDSMPN #ClonalEvolution #MedicalEducation #HemeOnc #HEMEHUB
April 27, 2026 at 7:47 PM
🩸 Further insights on treatment options for CMML
#CMML #MyeloidMalignancies #Hematology #LeukemiaResearch #RASMutations #KRASInhibitors #TargetedTherapy #PanRAS #Immunotherapy #TIM3 #LILRB4 #MDSMPN #ClonalEvolution #MedicalEducation #HemeOnc #HEMEHUB
#CMML #MyeloidMalignancies #Hematology #LeukemiaResearch #RASMutations #KRASInhibitors #TargetedTherapy #PanRAS #Immunotherapy #TIM3 #LILRB4 #MDSMPN #ClonalEvolution #MedicalEducation #HemeOnc #HEMEHUB
Hundreds of women living with ovarian cancer could benefit from the first new NHS drug for hard-to-treat ovarian cancer in more than 20 years.
healthcaretoday.com/article/brea...
#OvarianCancer #NHS #TargetedTherapy #CancerResearch #Oncology
healthcaretoday.com/article/brea...
#OvarianCancer #NHS #TargetedTherapy #CancerResearch #Oncology
Breakthrough ovarian cancer drug to benefit hundreds of women
Drug, which targets cells directly, offers better quality of life for those with hard-to-treat ovarian cancer.
healthcaretoday.com
June 19, 2026 at 8:33 AM
Hundreds of women living with ovarian cancer could benefit from the first new NHS drug for hard-to-treat ovarian cancer in more than 20 years.
healthcaretoday.com/article/brea...
#OvarianCancer #NHS #TargetedTherapy #CancerResearch #Oncology
healthcaretoday.com/article/brea...
#OvarianCancer #NHS #TargetedTherapy #CancerResearch #Oncology
A new blood test developed by The Institute of Cancer Research predicts how well patients with advanced breast cancer will respond to targeted therapies.
healthcaretoday.com/article/brea...
#Healthcare #BreastCancer #TargetedTherapy #PatientSafety
healthcaretoday.com/article/brea...
#Healthcare #BreastCancer #TargetedTherapy #PatientSafety
February 4, 2026 at 9:33 AM
A new blood test developed by The Institute of Cancer Research predicts how well patients with advanced breast cancer will respond to targeted therapies.
healthcaretoday.com/article/brea...
#Healthcare #BreastCancer #TargetedTherapy #PatientSafety
healthcaretoday.com/article/brea...
#Healthcare #BreastCancer #TargetedTherapy #PatientSafety
This #IJEM study presents MPI-traceable alginate magnetic #Millirobots enabling integrated locomotion, magnetic heating, and real-time tracking, advancing #TargetedTherapy and minimally invasive #Biomedical applications.
#OpenAccess: doi.org/10.1088/2631...
#OpenAccess: doi.org/10.1088/2631...
March 31, 2026 at 2:02 PM
This #IJEM study presents MPI-traceable alginate magnetic #Millirobots enabling integrated locomotion, magnetic heating, and real-time tracking, advancing #TargetedTherapy and minimally invasive #Biomedical applications.
#OpenAccess: doi.org/10.1088/2631...
#OpenAccess: doi.org/10.1088/2631...